Gene BRCC-3 and diagnostic and therapeutic uses thereof
AssigneesGeorgetown University, NeoPharm, Inc.
InventorsUsha Kasid, Prafulla Gokhale, Deepak Kumar, Howard Boudreau, Imran Ahmad, Anatoly Dritschilo, Aquilur Rahman
Life of this patent
Estimating the term…
Abstract
A gene that is a modulator of tumor growth and metastasis in certain cancer types is provided. This gene and corresponding polypeptide have diagnostic and therapeutic application for detecting and treating cancers that involve expression of BRCC-3 such as breast cancer and lung cancer.
Claims31
An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:
- (a) a polynucleotide encoding amino acids from about 1 to about 529 of the amino acid sequence contained in SEQ ID NO:2;
- (b) a polynucleotide encoding amino acids from about 2 to about 259 of the amino acid sequence contained in SEQ ID NO:2;
- (c) the polynucleotide complement of the polynucleotide of
- (a) or (b);
- and
- (d) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).
An isolated nucleic acid molecule comprising about 2 to about 2468 contiguous nucleotides from the nucleic acid sequence contained in SEQ ID NO:1.
An isolated nucleic acid molecule comprising about 50 to about 200 contiguous nucleotides from the nucleic acid sequence identified in SEQ ID NO:1.
An isolated nucleic acid molecule comprising about 2 to about 1589 contiguous nucleotides of the nucleic acid sequence contained in SEQ ID NO:1.
An isolated nucleic acid molecule comprising about 10 to about 300 contiguous nucleotides from the nucleic acid sequence contained in SEQ ID NO:1.
An isolated nucleic acid molecule comprising a polynucleotide encoding a polypeptide wherein, except for at least one conservative amino acid substitution, said polynucleotide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2;
- and
- (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
An isolated polypeptide comprising amino acids at least 95% identical to amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 529 of the amino acid sequence contained in SEQ ID NO:2;
- and
- (b) amino acids from about 2 to about 529 of the open amino acid sequence contained in SEQ ID NO:2.
An isolated polypeptide wherein, except for at least one conservation amino acid substitution, said polypeptide has an amino acid sequence selected from the group consisting of:
- (a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2;
- and
- (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
An isolated polypeptide comprising amino acids selected from the group consisting of:
- (a) amino acids from about 1 to about 529 of the amino acid sequence in SEQ ID NO:2;
- and
- (b) amino acids from about 2 to about 529 of the amino acid sequence in SEQ ID NO:2.
An epitope-bearing portion of the polynucleotide identified in SEQ ID NO:2.
A method of modulating apoptosis or proliferation of a cancer cell, comprising regulating expression of BRCC-3 in said mammalian cell.
An antisense oligonucleotide that inhibits the expression of BRCC-3 in a mammalian cell.
A method of treating cancer characterized by BRCC-3 overexpression by administration of an antisense oligonucleotide or ribozyme that modulates BRCC-3 expression.
A method of treating cancer characterized by BRCC-3 overexpression comprising administering an antibody that specifically binds BRCC-3.
A method of detecting cancer characterized by BRCC-3 overexpression or BRCC-3 underexpression comprising detecting the levels of BRCC-3 expression and correlating said level of expression to the presence or absence of cancer.
A method of modulating cancer cell proliferation and/or metastasis in a cancer patient comprising administering a ribozyme or antisense oligonucleotide that modulates BRCC-3 expression.
Dependencies are inferred from the claim text.